Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

Recruiting

SarilumabSarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

Sponsor:

Sanofi

Code:

NCT07286214

Conditions

Polymyalgia Rheumatica

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

Sarilumab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-04. This information was provided to ClinicalTrials.gov by Sanofi on 2026-05-19.